Hazal Özdemir Koyu Highlights Inclusivity and Innovation in Cancer Nursing at EONS19 / cancer, EONS19, ESMO Congress 2026, ...
Uddiptya Goswami Highlights How ESMO 2026 Conversations Will Shape His Future Clinical Practice and Research / Aathithya Sp, ...
Jennifer S. Buell: Calling for Immediate Action to Expand Access to Promising Cancer Treatments ...
Jennifer S. Buell: Calling for Immediate Action to Expand Access to Promising Cancer Treatments ...
At the ESMO Congress 2026 Presidential Symposium III, Domenica Lorusso (Pieve Emanuele, Italy) presented results from the phase III TroFuse-005/ENGOT-en23/GOG-3095 ...
Results from the phase UNION Phase III trial, presented by Zhen Yu Lin at ESMO 2026, demonstrated that short-course radiotherapy followed by camrelizumab and chemotherapy significantly improved ...
At the ESMO Congress 2026, Chenlei Wen (Shanghai, China) presented preliminary results from a Phase II study evaluating HRS-4642 plus gemcitabine and nab-paclitaxel (GnP), with or without adebrelimab, ...
At the ESMO Congress 2026, Jian Zhou (Shanghai, China) presented results from the Phase III HARMONi-GI1 trial (NCT06591520), evaluating ivonescimab plus chemotherapy versus durvalumab plus ...
At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...
A post hoc exploratory analysis of the phase III EMERALD-3 trial reported stable mean liver function scores during treatment with STRIDE, with or without lenvatinib, plus transarterial ...
SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer / cancer, ESMO, esmo 2026, ...
At the ESMO Congress 2026, Daniel Y. Heng (Calgary, Canada) presented the final analysis of the Phase III LITESPARK-011 trial (NCT04586231), evaluating belzutifan plus lenvatinib compared with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results